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Abstract: Background: Respiratory muscle dysfunction is an important health problem with high
morbidity and mortality and associated costs in patients with bronchiectasis (BC). The aim of this study
was to analyse the effects of therapeutic respiratory muscle training (RMT) interventions on improving
sputum clearance, ventilator function, muscle strength and functional capacity in BC. Methods:
Systematic review and meta-analysis were conducted following PRISMA guidelines. Two independent
investigators searched using several electronic databases. The methodological quality of nine studies
was assessed using the PEDro scale. Study selection/eligibility criteria: The following were included:
randomised controlled trials, randomised crossover trials and pilot studies of patients with BC
that used the intervention as RMT (inspiratory/expiratory) and evaluations of respiratory muscle
strength (maximal expiratory pressure/maximal inspiratory pressure). This systematic review was
registered in PROSPERO (CRD42017075101). Nine studies were included, five of which obtained
an A recommendation grade, three with B, and one with C. Study quality was poor to good (mean
PEDro Score of 6.375 out of 10). Studies had small sample sizes (8–98). Results show improvements
on PImax in favour of therapeutic respiratory muscle training intervention (MD = 6.08; 95% CI = 1.38,
10.77; p < 0.01; I2 = 92%). However, high heterogeneity was identified on meta-analysis.
Keywords: bronchiectasis; respiratory muscle training; respiratory muscle strength; maximum
inspiratory pressure; maximum expiratory pressure; meta-analysis
1. Introduction
Bronchiectasis (BC) is a chronic respiratory condition characterised by bronchial dilatation
secondary to airway inflammation, infection and dysfunction of mucociliary clearance [1–4]. BC,
permanent damage and widening of one or more of the large connecting bronchi (airways) may occur
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in nearly one third of individuals with chronic obstructive pulmonary disease (COPD) [1]. A variety of
factors may affect the efficacy of inspiratory muscle training, including the degree of lung hyperinflation
and severity of airway obstruction [5]. Both cause dyspnoea, which is a symptom of respiratory failure;
inspiratory muscle weakness may lead to muscle load and capacity discordance.
BC is heterogeneous in its clinical features, causes and outcomes [6]. Respiratory secretions in
individuals with BC have poor transport properties, which manifest as reduced mucociliary transport,
higher contact angle, dyspnoea and decreased exercise tolerance [6]. BC is an important health problem
with high morbidity, mortality and associated costs [7]. International guidelines for managing BC
include referral to pulmonary rehabilitation (PR) that improves exercise tolerance and quality of life [8,9].
The current evidence stresses the importance of the future development of process and performance
metrics to monitor PR programs, to be able to start international benchmarking, and to provide
recommendations for international standards based on evidence and best practice [10]. Previous to
therapeutic respiratory muscle training (RMT) intervention, airway clearance techniques (ACTs) have
been an important component in the management of patients with bronchiectasis [11]. Previous studies
indicated the importance of mobilising secretions and facilitating effective expectoration in order to get
improving airway clearance [11–13].
There are two distinct types of specific therapeutic RMT interventions, namely respiratory muscle
strength (resistive/threshold) training (RMST) and respiratory muscle endurance (hyperpnoea) training
(RMET), which have been established to improve the endurance performance of healthy individuals [14].
Various methods of therapeutic RMT interventions have been described. Firstly, RMST performed
by breathing against an external inspiratory and/or expiratory load. This load consists either of a
flow-dependent resistance or of a pressure threshold that needs to be overcome and sustained to
generate flow. When a patient breathes against an external expiratory load, these devices are known
as positive expiratory pressure trainers (PEP). Secondly, patients perform concurrent inspiratory and
expiratory muscle training (CRMT). Third, patients clean bronchial by oscillatory or temporary PEP
training devices. Finally, target flow and target pressure respiratory muscle training is where patients
are trained to generate a target respiratory flow rate through a fixed resistance.
Previous studies have supported, with a B recommendation grade, offering the use of IMT
(inspiratory muscle training) in conjunction with conventional PR to enhance the maintenance of the
training effect [15]. IMT provides breathing training together with resistance loading produced by a
valve and was regarded as a mixture of strength and endurance training [16]. Two smaller studies
yielded consistent results supporting the use of either inspiratory or expiratory pressure threshold
load breathing exercises to improve pulmonary muscle strength in people with BC [5,17]. However,
there are several unanswered issues regarding intensity, frequency and duration of training, as well as
the optimal strategy for maintenance of benefit for patients with BC [18]. There is still scarce literature
regarding the benefits of physical training and long-term effects in BC [12,19–21]. Therefore, it is
necessary to establish the most effective management strategies at the earliest stage possible.
The major purpose of this research is to detect recommendation grades regarding therapeutic
RMT interventions in BC. This systematic review and meta-analysis examined the available evidence of
different modalities of therapeutic RMT interventions that improve sputum clearance and respiratory
muscle weakness in BC. Hence, the most suitable protocol to improve the respiratory muscle weakness
and the respiratory function must be established.
2. Methods
2.1. Search Strategy
This systematic review was performed following the PRISMA guidelines (Preferred Reporting
Items for Systematic Reviews and Meta-Analysis) [22]. The PRISMA Checklist is detailed in Appendix A.
The review protocol was registered with an international registration database (PROSPERO, Registration
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Number: CRD42017075101). All analyses were performed on data of previously published studies,
and thus no ethical approval and patient consent were required.
A literature search was performed to identify the clinical studies that addressed the effect of
instrumental mechanical devices for RMT in BC. The following databases were searched for relevant
studies: MEDLINE (PubMed), Physiotherapy Evidence Database (PEDro), Cochrane Database of
Systematic Reviews and CINAHL. Two reviewers carried out several searches in the databases using
combinations of key words: bronchiectasis, respiratory muscle training, respiratory muscle strength,
maximum inspiratory pressure and maximum expiratory pressure. The search strategy is detailed in
Appendix B. The research was limited to studies published between 2004 and November 2019.
2.2. Inclusion and Exclusion Criteria
Our research question was established following from the PICO (population, intervention,
control/comparison and outcomes) model. First, this review describes non-cystic fibrosis BC confirmed
in adults by clinical history, such as coughing, shortness of breath and exertional dyspnoea, pulmonary
function tests and high-resolution computed tomography (HRCT) [5,17]. It was necessary to have
a clinically stable disease with no requirements of antibiotics in the four weeks prior to starting the
study [12,20,23]. Clinical trials, randomised controlled trials and pilot studies that used therapeutic
RMT interventions were included.
The articles that did not use threshold trainers or did a postural drainage were excluded [24–26].
Studies were excluded if steroids (inhalation or oral) such as Salbutamol were used [27]. Studies were
excluded if patients were experiencing an acute exacerbation [25]. An acute exacerbation was defined
as the presence of four out of 12 symptoms of a respiratory exacerbation, and requiring a course of oral
antibiotics [28].
2.3. Quality Assessment and Data Extraction
Two independent reviewers (MJCH and RMV) completed the assessment list based on the PEDro
score. This scale (0–10) is based on the list developed by Verhagen et al. [29], and assesses the internal
validity of randomised controlled trials. A study with a PEDro score of 6 or more is considered level-1
evidence (6–8: good; 9–10: excellent) and a score of 5 or less is considered level-2 evidence (4–5: fair; <4:
poor) [30]. The methodological quality of the eight studies was evaluated using the PEDro scale [30–32].
Disagreements between authors were initially resolved via discussion, and then by consultation with a
third reviewer (JAMM).
The following characteristics were extracted: different therapeutic RMT interventions, namely
inspiratory or expiratory exercises. Firstly, therapeutic inspiratory muscle intervention could be
performed with different intensities and duration exercises through resistance offered by a valve
threshold, adapting to the needs and changes of the individual as it progressed through the study.
Secondly, therapeutic expiratory muscles intervention included four different types of instrumental
mechanical devices: flutter, Acapella, UNIKO-TPEP® and Origen-Dual Valve®.
The outcome measures included were maximum inspiratory pressure (PImax) [5,17], maximum
expiratory pressure (PEmax) [5,12,20,23], respiratory muscle strength, forced vital capacity
(FVC) [5,12,20,27], and maximum oxygen consumption or VO2 peak [17]. Other used measures
included the sputum volume (SV) [11] or measurement of respiratory mechanics associated with
peripheral airway resistance (such as the first derivative of resistance as a function of frequency) [33],
transport velocity (TV) [34], exercise capacity (Six Minute Walk test (6MWT)) [5,20] and hand
dynamometry (using a Jamar hydraulic) [21]. Regarding anthropometric outcomes related with
body composition, Body Mass Index (BMI) and Fat Free Mass Index (FFMI) with Dual-energy X-Ray
Absorpiometry (DEXA), mid-arm muscle circumference (MAMC), and phase angle by Bio-impedance
were found [21]. Self-Reported outcomes measures included The Borg Scale, St George’s Respiratory
Questionnaire [5,12,20], Quality of Life Questionnaire for Bronchiectasis (QOL-B-Spain-v3.0) and a
seven-day prospective dietary questionnaire [21].
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The results for the primary and secondary outcome measures were described and where possible
study results were pooled and meta-analysis was conducted. Effect size (ES) was calculated using
the difference between the mean (MD) and the standard deviation of the difference (SMD) with
95% confidence intervals (95% CI). An alpha value <0.05 was considered as statistically significant.
We decided to pool studies based on comparing the RMT and control group.
The ES values were used to compare the different modalities of therapeutic RMT intervention
with control group. Analysis of the effect size values was based on Cohen’s work, which determined
that values below 0.2 were considered to have no effect, those between 0.2 and 0.5 as small effect, those
between 0.5 and 0.8 a medium effect, and those above 0.8 a major effect [35]. The recommendation
grades were studied according to the Duodecim (Finnish Medical Society Duodecim), a clinical practice
guide developed in Finland to improve the quality of health care [36]. Grade A means that the
recommendation is based on strong evidence. Grade B is based on sufficient evidence to make a
clear recommendation. Grade C recommendations are based on limited evidence. Grade D refers to
recommendations for which there is no evidence based on clinical studies [37].
2.4. Statistical Analysis
A meta-analysis was applied to compare changes in the effect size (post-intervention and
pre-intervention) between the intervention group and the control group. For the meta-analysis,
the standardised mean difference was calculated along with the 95% confidence interval, with a
significance level set to p < 0.05. Heterogeneity was determined by the chi-square test and the I2
statistic. The results of all the subgroups included in this meta-analysis were represented in Forest
plots. The statistical analyses were carried out with the statistical software REVIEW MANAGER 5.3
(The Cochrane Collaboration) (The Nordic Cochrane Centre 2014).
3. Results
3.1. Study Selection and Methodological Quality Assessment
The initial database searches returned sixty-three potential studies. Sixteen relevant papers
were found in the search strategy, and nine studies fulfilled the inclusion criteria (Figure 1). After
reviewing titles and abstracts, fifteen papers were selected for full-text evaluation. Of these, nine
papers were included in the systematic review and meta-analysis. Table 1 shows the assessment of
methodological quality according to PEDro scale (mean PEDro score of 6.375 out of 10). We found
seven studies [5,17,21,23,33,38,39] with level 1 evidence (good; 75% [7/9]); one study [20] had score of 5,
which is considered level 2 evidence (acceptable; 12.5% [1/9]); and another study [12] had scores of 4 or
less, which is considered (poor; 12.5% [1/9]). Trials were considered of enough methodological quality
if they had a score of at least 5 out of 10 points. This was based on the fact that the tests with a score
close to 4 do not employ a triple blind methodology (i.e., patient, evaluator and providing treatment).
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Table 1. PEDro score for Methodological Quality assessment of nine studies.
Section/Theme Ozalp[39]
Venture Lli
[23]
Liaw
[5]
Newall
[17]
Olveira
[21]
Tambascio
[40]
Figueiredo
[33]
Mandal
[20]
Murray
[12]
Eligibility criteria Yes Yes Yes Yes Yes Yes Yes Yes Yes
Randomly
allocated Yes Yes Yes Yes Yes Yes Yes Yes Yes
Concealed
allocation No Yes Yes Yes Yes Yes Yes No No
Comparability of
base Yes Yes Yes Yes Yes Yes No Yes No
Blinding of
subjects Yes Yes No No No No No No No
Blinding of
therapist No No Yes No No No Yes No No
Blinding of
assessor Yes No Yes No No No No No No
Proper
Continuation Yes Yes No Yes Yes No No Yes Yes
Intention to treat Yes Yes Yes Yes Yes Yes Yes No No
Between-group
statistical
comparison
Yes Yes Yes Yes Yes Yes Yes Yes Yes
Point measure and
measures of
variability
Yes Yes Yes Yes Yes Yes Yes Yes Yes
Total 8 8 8 7 7 6 6 5 4
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3.2. Study Design and Population Characteristics
Nine studies with a total of 262 participants clinically diagnosed with BC were included in
this systematic review. Protocol characteristics, intensity of training, recommendation grades, effect
size of clinical and self-reported outcomes are described in Table 2. Regarding therapeutic RMT
interventions, namely inspiratory or expiratory exercises, we first found three studies: two randomised
controlled trials [5,17] about therapeutic inspiratory muscle intervention. Besides, two different types
of interventions were carried out [5,17]. Two groups were made: maximum controlled inspiratory
training and non-intervention [5], in front of three groups were made: PR plus sham IMT (PR-SHAM),
PR plus targeted IMT (PR-IMT), or control [17].
It was found that two of the studies reviewed used the Threshold trainer [5,17]. Regarding
airway clearance, one study used Flutter VRP1 [40], one used Flutter valve TM [33], one used the
UNIKO-TPEP® [23], and two studies used oscillatory positive expiratory pressure (OPEP) device
Acapella [12,20]. Furthermore, there is the Origen-Dual Valve [21], which allows both simultaneous
and sequential dual training work (expiratory and inspiratory muscles).
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Table 2. Key findings of primary studies.
Study, DR PEDro, Type of Study,Sample Size Training Protocol Intra-Group Outcomes
Effect Size (%) Clinical OC
Measures
Effect Size (%)
Self-Reported OC Measures
Venturelli, 2013
[23]
A
PEDro: 8/10
Randomised controlled
trial
n = 98
10 days twice a day 20-min cycles
of manually assisted breathing
techniques plus 15 min of
temporary PEP
PImax p = 0.541
PEmax p = 0.233
FVC p = 0.495
PImax + 6% pred
PEmax + 2.3% pred
FVC + 4.3% pred
Liaw, 2011 [5]
A
PEDro: 8/10
Randomised
controlled trial
n = 26
8 week
5 days/week
30 min/day
I: 30% MIP increasing 2 cm
H2O/week
↑PImax p = 0.004
↑PEmax p = 0.004
↑6MWD p = 0.021
FVC p = 0.309
PImax + 23.85 cm H2O
PEmax + 31.92 cm H2O
6MWD + 61.31 m
FVC + 2.51% pred
TBS 1.46
SGRQ 32.46
Ozalp, 2019 [39]
A
PEDro: 8/10
Randomised
controlled trial
n = 45
8 week
3 days/week
Only 1 ss/week was performed
under the supervision
I: target workload was selected
from 30% (first session) to 70%
(third session) of MIP
↑PImax p = 0.001
↑PEmax p = 0.233
SIP p < 0.05
ISWT distance
PImax + 2.62 cm H2O
PEmax + 1.039 cm H2O
↓FSS
−0.197 p = 0.05
↑LCQ
0.52 p = 0.05
Newall, 2005 [17]
A
PEDro: 7/10
Randomised
controlled trial
n = 32
8 week
3 days/week
2 sets/day
15 min/set
I: 30% MIP and increased 5% each
week until a training I of 60% MIP
↑PImax p = 0.003
Vo2 peak p = 0.192
PImax (cm H2O):
PR-sham 12, PR-IMT 21.4;
PR-control − 1.6
Vo2 peak(ml/min/kg):
PR-sham 1.96; PR-IMT 0.35;
PR-control − 1.91
ISWT (m): PR-sham 96.7; PR-IMT
124.5
PR-control 11
EE (m): PR-sham 392.8
PR-IMT 607.3; PR-control − 112.6
Murray, 2009 [12]
A
PEDro: 4/10
Randomised crossover
trial
n = 20
3 months of twice daily, each ss
20–30 min, 3 sets, 10 breath/set
PImax p = 0.2
PEmax p = 0.3
FVC p = 0.6
PImax +4.5 cm H2O
PEmax − 1.5 cm H2O
FVC + 0.18 L
↓ SGRQ 0.7
p = 0.004
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Table 2. Cont.
Study, DR PEDro, Type of Study,Sample Size Training Protocol Intra-Group Outcomes
Effect Size (%) Clinical OC
Measures
Effect Size (%)
Self-Reported OC Measures
Mandal, 2012 [20]
C
PEDro: 5/10
RCT
n = 30
8 weeks, 3sets/ss, 20–30 min/ss
Twice a day
CG: chest physiotherapy
IG: chest physiotherapy plus PR
CG: PImax + 5.9 cm H2O
PEmax + 5.3 cm H2O
ISWT − 4.6 m
IG: PImax + 6.6 cm H2O
PEmax + 14.7 cm H2O
ISWT + 56.7 m
CG: SGRQ 1.4
IG: ↓ SGRQ 4
p < 0.001
Tambascio, 2011
[40]
B
PEDro: 6/10
RCT crossover
n = 18
4 weeks with Flutter VRP1® 30
min daily and 1 weeek of a
“wash-out” period vs. Flutter
therapy
Flutter Therapy
↓CAM: 6.11 ± 0.5◦
p > 0.05
Figueiredo, 2012
[33]
B
PEDro: 6/10
RCT crossover
n = 8
Flutter Valve TM vs Sham Flutter
(placebo) 8.4 mL more secretions
Olveira, 2015 [21]
B
PEDro: 7/10
RCT parallel groups
n = 30
12 weeks PR 45 min +15 min with
Orygen-Dual Valve®
3 days/week (one unsupervised
ss)
BMD: 0.013 ± 0.002
FFM: 1.1 ± 0.1 p > 0.01
↑FFMI:0.4 p > 0.01
Maximal Handgrip: 2.2 p > 0.01
QOL-B: 8.1 ± 4.6
p > 0.05
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3.3. Meta-Analysis
The meta-analysis of the data of the RCTs was performed using the fixed effects model, as
presented in Figures 2 and 3. Because of the high heterogeneity, the sensitivity analysis was performed
in relation to the type of training and intensity, analysing those RCT papers that used outcomes of
PImax and PEmax. Therefore, the present review strengthens the evidence regarding the efficacy of
respiratory muscle training for increasing respiratory muscle strength, because this review was based
on meta-analyses of randomised trials with reasonable quality (mean PEDro Score of 6.375 out of 10).
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Pooled analysis of the four studies measuring PImax showed a significant overall effect in favour
of intervention (MD = 6.08; 95% CI = 1.38, 10.77; p < 0.01; I2 = 92%) (Figure 2). However, pooled
analysis of the three studies measuring PE ax i ot s ow a significant overall effect (MD = 2.04;
95% CI = −3.3 , 7.31; p < 0.01; I2 ) (Figure 3).
4. Discu sion
This systematic review sum arises reco ation grades of various therapeutic RMT
interventio s i BC. It was observed that RMT may improve PImax and PEmax s r ngth of respiratory
muscl s i this population [5,17,23]. These benefits in respi atory uscles have lso b en found in
pati nts with ltiple sclerosis (MS) [41] and chronic obstructive pulmonary dise s (COPD) [42].
There are scarce studies about RMT in BC. After performing this systematic review, eight studies about
therapeutic RMT intervention in BC were carried out [5,12,17,20,21,23,33,40]. Three studies reviewed
used the Threshold trainer [5,17]. Three studies were conducted about bronchial clearance with PEP
with Flutter VRP1 [33,40], three studies used Acapella [12,20], one used Origen-Dual Valve® [21], and
one used the UNIKO-TPEP® [23]. RMT could be performed using either inspiratory or expiratory
muscle devices. Only one study compared the value of inspiratory versus expiratory training in
patients with BC [11].
Three primary do uments ith an “ ” recommendation grade for IMT were included n this
revi w [5,17,39]. According to the treatment with positive xpiratory pres ure (PEP), two studies were
found with an “A” recommendation grade where there were improvements on lung function and
symptoms in patients with chronic lung disease and mucus hyper-secretion [12,23].
Firstly, Newall et al. carried out an IMT protocol of eight weeks, three days per week, two sets per
day and 15 min per set, with an intensity of 30% MIP with Threshold Trainer, which was increased by
5% each week until a training intensity of 60% PImax was reached [17]. Three groups were made: a PR
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plus sham IMT (PR-SHAM), a PR plus targeted IMT (PR-IMT), and a control group, which did not
carry out the training. At the end of the protocol, the PR-SHAM increased the PImax +12 cm H2O
(1.1 to 22.9 cm H2O) and the PR-IMT increased the PImax +21.4 cm H2O (9.3 to 33.4). The PImax for
the control group came down −1.6 (−6.2 to 3.0). Regarding exercise capacity, Newall et al. found
improvement for the incremental shuttle walking test (ISWT) in the three groups (PR-SHAM +96.7 m,
PR-IMT +124.5, control group +11 [17].
Secondly, Liaw et al. performed an IMT protocol of eight weeks of duration, for minimum five
days per week, 30 min per day, starting with an intensity of 30% of PImax and increasing it 2 cm H2O
each week. At the end of the protocol, all outcomes were statistically significant. Thus, the effect sizes
increased for PImax + 23.85 cm H2O (p = 0.004), PEmax was + 31.92 cm H2O (p = 0.004), the 6MWT +
61.31 (p = 0.021) and the FVC was + 2.51% predictive (pred) (p = 0.309). Other outcomes such as the
Borg Scale and the St George’s Respiratory Questionnaire also improved, coming down 1.46 and 32.46,
respectively [5]. However, only one study measured with Leicester Cough Questionnaire [39].
Third, Venturelli et al. also carried out an EMT protocol of 10 days, twice a day, for 15 min
with the Positive Expiratory Pressure (PEP) divide plus 20-min cycles of manually assisted breathing
techniques. At the end of the protocol, PImax was increased + 6% pred (p = 0.541), PE max increased +
2.3% pred (p = 0.233) and the FVC increased + 4.3% pred (p = 0.495) [23]. The treatment with the PEP
showed improvements in PImax and PEmax, with an increase of 6% pred and 2.3% pred, respectively.
Therefore, temporary PEP not only improves symptoms in patients with chronic pulmonary disease
and mucus hypersecretion, but also improves the strength and endurance of respiratory muscles [23].
Murray et al. performed an EMT protocol with Acapella for 12 weeks, twice daily, for 20–30 min
per session, and three sets of 10 breaths per set. Thus, the effect sizes increased for PImax + 4.5 cm H2O
(p = 0.2), the FVC was + 0.18 L (p = 0.6), but came down for PEmax −1.5 cm H2O (p = 0.3). At the end
of the protocol, only St George’s Respiratory Questionnaire was statistically significant, coming down
0.7 (p = 0.004) [12]. This study found that regular chest physiotherapy in BC has significant benefits
compared with no chest physiotherapy [12].
Moreover, one pilot study with “C” recommendation grade used Acapella for eight weeks [20].
Mandal et al. found improvements of respiratory muscle strength after therapeutic RMT intervention,
where a chest physiotherapy group and chest physiotherapy plus pulmonary rehabilitation group
were performed [20]. Both groups improved their outcomes, but the improvements in the chest
physiotherapy plus pulmonary rehabilitation group (IG) (PImax + 6.6 cm H2O, PEmax + 14.7 cm H2O,
FVC 0.2L) were greater than those of the chest physiotherapy group (CG) (PImax + 5.9 cm H2O, PEmax
+ 5.3 cm H2O, FVC 0L). Regarding physical capacity, the incremental shuttle walking test also increased
in the chest physiotherapy plus pulmonary rehabilitation (+56.7 m) and the St George’s Respiratory
Questionnaire also improved, decreasing 8 in IG and 1.4 in CG [20]. Furthermore, regarding airway
clearance devices, chest physiotherapy with Acapella should be carried out for 12 [12] or 8 weeks [20],
twice a day according to revised studies in this systematic review.
Only one study evaluated the effect of PR versus PR plus hyperproteic oral nutritional supplement
enriched with beta-hydroxy-beta-methylbutyrate (HMB) on body composition, health related quality
of life, skeletal muscle strength and plasma levels of prealbumin and myostatin. People with BC
performed PR coupled with 15 min of breathing retraining with the Orygen-Dual Valve®, which allows
both simultaneous and sequential dual training work (expiratory and inspiratory muscles) [21].
5. Limitations
There were two limitations on therapeutic RMT interventions for people with BC. First, small
sample sizes reduced the ability to detect the effects of treatment. In addition, studies were designed
with a follow-up period that was not long enough, with 12 weeks as the longest protocol [21]. Therefore,
it might be interesting to extend the intervention period to six months or even a year.
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6. Future Research
Further research would be necessary to consider the effects that different training protocols
(duration of the inspiratory or expiratory training, frequency of sessions, high intensity of the
respiratory muscles training program, and exercise capacity) may have on people with BC and to
determine the range of the changes in outcomes associated with respiratory muscles training. It would
also be necessary to take into account a training protocol for the respiratory muscles proposed, in
which inspiratory muscle training, expiratory muscle training or both types of respiratory training
work together for people with BC.
7. Clinical Implications
To our knowledge, this is the first systematic review to include only randomised or
quasi-randomised clinical trials and to examine the effects of respiratory muscle training on the
inspiratory and expiratory muscles for people with BC.
8. Conclusions
There were improvements in the strength of the respiratory muscles during therapeutic RMT
intervention with a threshold trainer as a way of treatment for muscles weakness. Three revised articles
with “A” grade recommendation covered a protocol of eight weeks, with a frequency of three or five
days per week, with one or two daily sessions, each session consisting of 30 min per day or 15 min per
set, two sets per day, with an intensity of 30% of PImax.
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BMD bone mineral density
CAM contact angle measurement
CG control group
DR Degrees of Recommendation
EE endurance exercise
FFM Fat free mass
FFMI Fat free mass index
FVC forced vital capacity
FRC functional residual capacity
FSS Fatigue Severity Scale
I intensity
IG intervention group
ISWT incremental shuttle walking test
LCQ Leicester Cough Questionnaire
MBC maximum breathing capacity
PEmax maximal expiratory pressure
MIE maximal inspiratory effort
min minute
PImax maximal inspiratory pressure
OC outcome
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PEDro Physiotherapy Evidence Database
PEP positive expiratory pressure
PPS patient preference scale
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analysis
PR pulmonary rehabilitation
PR-control pulmonary rehabilitation control group
PR-IMT pulmonary rehabilitation inspiratory muscle training group
PR-sham pulmonary rehabilitation sham group
QOL-B quality of Life for BC
SGRQ St George’s Respiratory Questionnaire
RV residual volume
ss session
SIP sustainable inspiratory pressure
SV sputum volume
TBS The Borg Scale
TIMT threshold inspiratory muscle trainer
TLC Total Lung Capacity
TV transport velocity
VRP1® type of Flutter
6MWD 6 Minute-Walking Distance
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Appendix A. PRISMA 2009 Checklist
Title
Title 1 Identify the report as a systematic review, meta-analysis, or both. 1
Abstract
Structured summary 2
Provide a structured summary including, as applicable: background; objectives; data sources; study
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results;
limitations; conclusions and implications of key findings; systematic review registration number.
Abstract page
Introduction
Rationale 3 Describe the rationale for the review in the context of what is already known. 1–2
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions,comparisons, outcomes, and study design (PICOS). 3
Methods
Protocol and
registration 5
Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available,
provide registration information including registration number. 3
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., yearsconsidered, language, publication status) used as criteria for eligibility, giving rationale. 3–4
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors toidentify additional studies) in the search and date last searched. 3
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it couldbe repeated. Appendix B
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, ifapplicable, included in the meta-analysis). 3–4
Data collection
process 10
Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any
processes for obtaining and confirming data from investigators. 3
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptionsand simplifications made. 4
Risk of bias in
individual studies 12
Describe methods used for assessing risk of bias of individual studies (including specification of whether
this was done at the study or outcome level), and how this information is to be used in any data synthesis. 5–11
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). 5–11
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures ofconsistency (e.g., I2) for each meta-analysis. 4
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Section/Topic # Checklist Item Reported on Page #
Risk of bias across
studies 15
Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias,
selective reporting within studies). 4
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), ifdone, indicating which were pre-specified. Not aplicable
Results
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons forexclusions at each stage, ideally with a flow diagram. Page 5, Figure 1
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-upperiod) and provide the citations. Page 7–9, Table 2
Risk of bias within
studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). Table 1
Results of individual
studies 20
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
Table 2
Figures 2 and 3
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. Figures 2 and 3
Risk of bias across
studies 22 Present results of any assessment of risk of bias across studies (see Item 15). Not aplicable
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [seeItem 16]). Not aplicable
Discussion
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider theirrelevance to key groups (e.g., healthcare providers, users, and policy makers). 9–11
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incompleteretrieval of identified research, reporting bias). 13
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications forfuture research. 14
Funding
Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role offunders for the systematic review. 14
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med
6(7): e1000097. doi:10.1371/journal.pmed1000097.
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Appendix B. Detailed Search Strategy
N◦ Terms used
#1 “Respiratory muscle training”
#2 “Respiratory muscle strength”
#3 “Maximum inspiratory pressure”
#4 “Maximum expiratory pressure”
#5 “Bronchiectasis”
PUBMED (63 potential articles):
((((((“respiratory muscle training” [Title/Abstract]) OR “respiratory muscle strength” [Title/Abstract]) OR
“maximum inspiratory pressure” [Title/Abstract]) OR “maximum expiratory pressure”[Title/Abstract])
AND “bronchiectasis” [Title/Abstract] Filters: Clinical Trial; Randomized Controlled Trial.
PEDro (3 potential articles):
• #1 AND #2AND #5 (1 potential article AND 1 RS)
• #2 AND #5(1 potential article AND the same RS)
• #3 AND #5 (1 potential article AND the same RS)
• #4 AND #5(1 potential article)
Cochrane Database of Systematic Reviews (4 potential articles):
• #1 AND #2 AND #5 (1 potential articles)
• (#1 OR #2) AND #5(2 potential articles)
• (#3 OR #4) AND #5 (1 RS)
• #3 AND #4 AND #5 (2 potential articles)
• (#1 OR #2 OR #3) AND #5 (2 potential articles)
• (#1 OR #2 OR #4) AND #5 (2 potential articles)
• (#1 OR #3 OR #4) AND #5 (1 potential article AND 1 RS)
• (#2 OR #3 OR #4) AND #5 (1 potential article)
CINAHL (40 potential articles):
• #1 AND #5 (10 potential article)
• #5 AND (#1 OR #2) (30 potential articles)
• #3 AND #4 AND #5 (1 potential article)
• #3 AND #5 (1 potential article)
• #4 AND #5 (1 potential article)
Note: only search strategies with results are shown.
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